Results 211 to 220 of about 2,154,176 (393)

Advancements in Protein Kinase Inhibitors: From Discovery to Clinical Applications. [PDF]

Research (Wash D C)
Baldi S, Long N, Ma S, Liu L, Al-Danakh A, Yang Q, Deng X, Xie J, Tang H.   +8 more
europepmc   +1 more source

Safety and efficacy of p38 mitogen-activated protein kinase inhibitors (MAPKIs) in COPD. [PDF]

Front Pharmacol, 2022
Yu H, Su X, Lei T, Zhang L, Feng Z, Zhang C, Zhang M, Wang Y, Chen X, Liu J.   +9 more
europepmc   +1 more source

Effect of protein kinase C inhibitor on ATP-induced steroidogeneis in bovine adrenocortical cells.

, 1994
Masahiro Kawamura, Haruhisa Nishi, Ken-ichi Kuboyama, Yuji Ohno   +3 more
openalex   +1 more source

Resveratrol Inhibits Porcine Intestinal Glucose and Alanine Transport: Potential Roles of Na+/K+-ATPase Activity, Protein Kinase A, AMP-Activated Protein Kinase and the Association of Selected Nutrient Transport Proteins with Detergent Resistant Membranes [PDF]

, 2018
Stefanie Klinger, G. Breves
openalex   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

Views of European Union medicine regulators and healthcare professionals on the approved versus prescribed dose of protein kinase inhibitors: an interview study. [PDF]

BMJ Open
Brinkhof M, de Vries ST, Mol PGM, Trapani D, Marije de Jong I, Broekman KE.   +5 more
europepmc   +1 more source

Reported hepatotoxicity and hepatotoxicity guidance in the product information of protein kinase inhibitors in oncology registered at the European Medicines Agency. [PDF]

Pharmacol Res Perspect, 2023
Maliepaard M, Faber YS, van Bussel MTJ.
europepmc   +1 more source

Activity of anti-cancer protein kinase inhibitors against Leishmania spp.

Journal of Antimicrobial Chemotherapy, 2014
Lisa Sanderson, V. Yardley, S. Croft
semanticscholar   +1 more source

Targeting p38α in cancer: challenges, opportunities, and emerging strategies

Molecular Oncology, EarlyView.
p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley   +1 more source

Targeting Neuroinflammation and Cognitive Decline: First-in-Class Dual Butyrylcholinesterase and p38α Mitogen-Activated Protein Kinase Inhibitors. [PDF]

J Med Chem
Ferjančič Benetik S, Proj M, Knez D, Košak U, Meden A, Krajšek K, Pišlar A, Horvat S, Švajger U, Tešić N, Pulkrabkova L, Soukup O, Skarka A, Andrys R, Brazzolotto X, Igert A, Nachon F, Dias J, Detka J, Gdula-Argasińska J, Wyska E, Szafarz M, Manik A, Płachtij N, Musílek K, Sałat K, Obreza A, Gobec S.   +27 more
europepmc   +1 more source